Newsquawk Logo

Vertex (VRTX) announces positive week 36 interim analysis results for primary and all secondary endpoints in the rainier phase 3 trial of povetacicept in adults with IGA nephropathy

Vertex's announcement of positive results from the rainier phase 3 trial marks a significant advance for their lead therapy, povetacicept, particularly given the potential pathway for accelerated FDA approval.

Newsquawk StaffPublished On the live feed at — 8 more headlines followed before this page went public
Newsquawk headlinesUTC

Smoke reported after strike on Bahrain's Babco oil refinery.

US Energy Secretary Wright says "we are talking" about coordinating releases from the SPR

Vertex (VRTX) announces positive week 36 interim analysis results for primary and all secondary endpoints in the rainier phase 3 trial of povetacicept in adults with IGA nephropathy

Newsquawk US Market Wrap: Stocks bid and crude hammered as Trump says war could be over soon

India reportedly seeks increased Russian oil imports amid Middle East disruptions. Russia could potentially double supplies, according to reports via Kommersant

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free
Free. No signup, no card.
  • To complete BLA for povetacicept by end of March for potential U.S. accelerated approval.
  • Povetacicept was generally safe and well tolerated
Context

This could elevate investor sentiment around the stock, influencing trends in the biotech sector and broader equity markets as the company prepares for its Biologics License Application (BLA) submission.

Related headlines

The whole workspace, free to try.

Try it free
Newsquawk Logo

© 2026 Newsquawk. All rights reserved.